Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors

NCT07137598 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07137598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07137598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Recruiting
Start date
December 5, 2025
Completion date
October 2, 2027
Enrollment
160 (estimated)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis